Contact us
Appointment
Appointment

Moderna mRNA-1195-P201 – Relapsing-Remitting Multiple Sclerosis (RRMS)

The HORIZON Trial is a clinical research study evaluating the safety and effectiveness of an investigational vaccine designed to help slow or stop the progression of multiple sclerosis (MS).

HORIZON Clinical Trial for Relapsing-
Remitting Multiple Sclerosis (RRMS)

This investigational vaccine targets the Epstein-Barr virus (EBV), a virus strongly linked to the development and progression of MS. Research shows that most people living with MS have been infected with EBV, and growing evidence suggests EBV may play a key role in triggering MS or worsening symptoms. By participating, individuals may help advance important research focused on addressing one of the underlying contributors to MS.

Frequently Asked Questions

Who May Qualify?

This clinical trial is enrolling adult participants who meet the following criteria:
  • Are 18 to 55 years of age
  • Have been diagnosed within the past 2 years with:
  • Relapsing-Remitting MS (RRMS)
  • Clinically Isolated Syndrome (CIS)
  • Radiologically Isolated Syndrome (RIS)
  • Are not pregnant and are not planning to become pregnant until after the final study injection
Additional eligibility requirements will be discussed with you by the study team.
RRMS is the most common form of multiple sclerosis. It is characterized by periods of new or worsening symptoms (relapses) followed by times of partial or complete recovery (remissions).
Research shows that most people with MS have been infected with EBV. Studies suggest EBV may play a role in triggering MS or contributing to disease progression, which is why it is being studied as a potential treatment target.
The HORIZON Trial is designed to evaluate the safety and effectiveness of an investigational vaccine aimed at slowing or stopping MS progression by targeting EBV. The study also helps advance future treatment options for people living with MS.

Accessibility Toolbar